Logo image of FSTX

F-STAR THERAPEUTICS INC (FSTX) Stock Fundamental Analysis

NASDAQ:FSTX - Nasdaq - US30315R1077 - Common Stock - Currency: USD

7.12  0 (0%)

After market: 7.12 0 (0%)

Fundamental Rating

2

Taking everything into account, FSTX scores 2 out of 10 in our fundamental rating. FSTX was compared to 561 industry peers in the Biotechnology industry. FSTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FSTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FSTX had negative earnings in the past year.
FSTX had a negative operating cash flow in the past year.
FSTX Yearly Net Income VS EBIT VS OCF VS FCFFSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M

1.2 Ratios

The profitability ratios for FSTX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FSTX Yearly ROA, ROE, ROICFSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FSTX Yearly Profit, Operating, Gross MarginsFSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -1K -2K -3K -4K -5K

More info and screens

3

2. Health

2.1 Basic Checks

FSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FSTX has more shares outstanding than it did 1 year ago.
FSTX has a worse debt/assets ratio than last year.
FSTX Yearly Shares OutstandingFSTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M
FSTX Yearly Total Debt VS Total AssetsFSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

FSTX has an Altman-Z score of 0.67. This is a bad value and indicates that FSTX is not financially healthy and even has some risk of bankruptcy.
FSTX has a Altman-Z score of 0.67. This is in the better half of the industry: FSTX outperforms 61.16% of its industry peers.
FSTX has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of FSTX (0.15) is worse than 65.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC8.16%
FSTX Yearly LT Debt VS Equity VS FCFFSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 3.38 indicates that FSTX has no problem at all paying its short term obligations.
FSTX has a Current ratio of 3.38. This is in the lower half of the industry: FSTX underperforms 67.45% of its industry peers.
A Quick Ratio of 3.38 indicates that FSTX has no problem at all paying its short term obligations.
FSTX's Quick ratio of 3.38 is on the low side compared to the rest of the industry. FSTX is outperformed by 66.19% of its industry peers.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.38
FSTX Yearly Current Assets VS Current LiabilitesFSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

FSTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.57%, which is quite impressive.
Looking at the last year, FSTX shows a quite strong growth in Revenue. The Revenue has grown by 18.64% in the last year.
The Revenue has been growing by 127.15% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)60.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
Revenue 1Y (TTM)18.64%
Revenue growth 3YN/A
Revenue growth 5Y127.15%
Sales Q2Q%49.8%

3.2 Future

FSTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.63% yearly.
Based on estimates for the next years, FSTX will show a quite strong growth in Revenue. The Revenue will grow by 12.21% on average per year.
EPS Next Y-39.55%
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%
EPS Next 5Y5.63%
Revenue Next Year-70.62%
Revenue Next 2Y-69.75%
Revenue Next 3Y-37.51%
Revenue Next 5Y12.21%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FSTX Yearly Revenue VS EstimatesFSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
FSTX Yearly EPS VS EstimatesFSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FSTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FSTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FSTX Price Earnings VS Forward Price EarningsFSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FSTX Per share dataFSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as FSTX's earnings are expected to decrease with -11.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%

More info and screens

0

5. Dividend

5.1 Amount

FSTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

F-STAR THERAPEUTICS INC

NASDAQ:FSTX (3/8/2023, 8:00:00 PM)

After market: 7.12 0 (0%)

7.12

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2023-03-13
Earnings (Next)05-08 2023-05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap156.51M
Analysts48.89
Price Target7.14 (0.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.03%
Min EPS beat(2)-47.48%
Max EPS beat(2)-4.58%
EPS beat(4)2
Avg EPS beat(4)120.51%
Min EPS beat(4)-47.48%
Max EPS beat(4)516.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1738.24%
Min Revenue beat(2)-100%
Max Revenue beat(2)3576.47%
Revenue beat(4)3
Avg Revenue beat(4)910.2%
Min Revenue beat(4)-100%
Max Revenue beat(4)3576.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.39
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 5.88
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.96
BVpS2.59
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.38
Quick Ratio 3.38
Altman-Z 0.67
F-Score2
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)80.51%
Cap/Depr(5y)224.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.54%
EPS Next Y-39.55%
EPS Next 2Y-23.23%
EPS Next 3Y-11.79%
EPS Next 5Y5.63%
Revenue 1Y (TTM)18.64%
Revenue growth 3YN/A
Revenue growth 5Y127.15%
Sales Q2Q%49.8%
Revenue Next Year-70.62%
Revenue Next 2Y-69.75%
Revenue Next 3Y-37.51%
Revenue Next 5Y12.21%
EBIT growth 1Y25.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.25%
EBIT Next 3Y-23.59%
EBIT Next 5Y-14.31%
FCF growth 1Y-57.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.9%
OCF growth 3YN/A
OCF growth 5YN/A